Literature DB >> 11742333

Anaplastic thyroid carcinoma: a 50-year experience at a single institution.

B McIver1, I D Hay, D F Giuffrida, C E Dvorak, C S Grant, G B Thompson, J A van Heerden, J R Goellner.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is among the most aggressive of human malignancies. However, there have been few large studies of histologically well-defined ATC. We report the results of a 50-year experience of this lethal malignancy.
METHODS: We reviewed all cases of ATC managed in this institution between 1949 and 1999. One pathologist (J.R.G.) reviewed all pathologic material. Clinical details were obtained from medical records, and current status of all patients was determined.
RESULTS: There were 134 cases, with a female-to-male ratio of 1.5:1 and a mean age of 67 years. Benign thyroid disease was present in 27 cases (20%) and well-differentiated thyroid carcinoma in 31 (23%). Sixty-two patients (46%) had distant metastases at diagnosis, and 98% of the tumors were locally invasive. Primary treatment was surgical for 96 patients (72%). Complete resection was achieved in 29 cases (30%), with "minimal residual disease" in 25. Neither extent of operation nor completeness of resection affected survival (P > .4). Postoperative radiotherapy gave slightly longer median survival (5 vs 3 months), which was not significant (P < .08). Multimodal therapy, including operation, chemotherapy, and radiotherapy, did not improve survival.
CONCLUSIONS: The outlook for patients with ATC remains grim. Novel treatments for ATC are desperately needed.

Entities:  

Mesh:

Year:  2001        PMID: 11742333     DOI: 10.1067/msy.2001.118266

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  111 in total

1.  A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Authors:  Keith C Bible; Vera J Suman; Michael E Menefee; Robert C Smallridge; Julian R Molina; William J Maples; Nina J Karlin; Anne M Traynor; Priya Kumar; Boon Cher Goh; Wan-Teck Lim; Ayoko R Bossou; Crescent R Isham; Kevin P Webster; Andrea K Kukla; Carolyn Bieber; Jill K Burton; Pamela Harris; Charles Erlichman
Journal:  J Clin Endocrinol Metab       Date:  2012-07-06       Impact factor: 5.958

2.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

3.  Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.

Authors:  I Hassan; A Wunderlich; E Slater; S Hoffmann; I Celik; A Zielke
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

4.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

5.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

6.  Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.

Authors:  Min Zhou; Yunyun Chen; Makoto Adachi; Xiaoxia Wen; Bill Erwin; Osama Mawlawi; Stephen Y Lai; Chun Li
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

7.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

8.  Epidermal growth factor receptor status in anaplastic thyroid carcinoma.

Authors:  Dae Ho Lee; Geon Kook Lee; Sun-Young Kong; Myoung Chul Kook; Sun Kyung Yang; So Yeon Park; Seong Hoe Park; Bhumsuk Keam; Do Joon Park; Bo Youn Cho; Seok Won Kim; Ki-Wook Chung; Eun Sook Lee; Sun Wook Kim
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

9.  Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Authors:  R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

Review 10.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.